These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 28657006)

  • 1. Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child-Pugh stage A liver cirrhosis.
    De Leeuw K; Woestenburg A; Verbeelen D
    NDT Plus; 2008 Dec; 1(6):412-413. PubMed ID: 28657006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
    Chiang SS; Chen JB; Yang WC
    Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comment on: 'Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child-Pugh stage A liver cirrhosis'.
    Smyth M; Gellert B; Pratt RD
    NDT Plus; 2009 Jun; 2(3):265-6. PubMed ID: 25984011
    [No Abstract]   [Full Text] [Related]  

  • 5. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF; Joy MS;
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
    Laville M
    Nephrol Ther; 2011 Jun; 7(3):154-61. PubMed ID: 21247818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving phosphate-binder therapy as a way forward.
    Hutchison AJ
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
    Finn WF; Joy MS; Hladik G;
    Clin Nephrol; 2004 Sep; 62(3):193-201. PubMed ID: 15481851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.
    Freemont AJ; Hoyland JA; Denton J;
    Clin Nephrol; 2005 Dec; 64(6):428-37. PubMed ID: 16370155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F; Hutchison AJ
    Int J Clin Pract; 2005 Sep; 59(9):1091-6. PubMed ID: 16115187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F; Hutchison AJ
    Expert Opin Pharmacother; 2005 Feb; 6(2):319-28. PubMed ID: 15757427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
    Joy MS; Finn WF;
    Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving outcomes in hyperphosphataemia.
    De Broe ME; D'Haese PC;
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i14-8. PubMed ID: 15126649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
    Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
    J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanthanum carbonate: a new phosphate binder.
    Behets GJ; Verberckmoes SC; D'Haese PC; De Broe ME
    Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):403-9. PubMed ID: 15199290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanthanum carbonate as a first-line phosphate binder: the "cons".
    Drüeke TB
    Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
    Hutchison AJ; Speake M; Al-Baaj F
    Nephrol Dial Transplant; 2004 Jul; 19(7):1902-6. PubMed ID: 15199195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.
    Hutchison AJ; Barnett ME; Krause R; J ; Siami GA;
    Clin Nephrol; 2009 Mar; 71(3):286-95. PubMed ID: 19281739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanthanum carbonate.
    Swainston Harrison T; Scott LJ
    Drugs; 2004; 64(9):985-96; discussion 997-8. PubMed ID: 15101790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
    Beaubien-Souligny W; Bezzaoucha S; Pichette V; Lafrance JP; Bell R; Lamarche C; Ouimet D; Vallee M
    Int Urol Nephrol; 2015 Jul; 47(7):1165-71. PubMed ID: 25982583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.